ResearcherUniversität UlmActive in the last 2 years
Angelika M. R. Kestler
Matched on ORCID iD 0000-0001-5214-9884; OpenAlex author ID A5034147176. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2023: 2 papers · 2024: none · 2025: 1 paper
Papers 3
- PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancr… Co-author DOI 10.1007/s10637-025-01526-7↗
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
- [Exocrine pancreatic cancer - what is new in the update of the S3 guideline?] First author DOI 10.1055/a-1932-0156↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas Theodor Werner Seufferlein · 2 shared papers, 2023 · strength 0.51
- Thomas Jens Ettrich · 2 shared papers, 2023–2025 · strength 0.33
- Paper PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitax… DOI 10.1007/s10637-025-01526-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Anke Reinacher‐Schick · 2 shared papers, 2023–2025 · strength 0.33
- Paper PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitax… DOI 10.1007/s10637-025-01526-7↗
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Morten Bækbo Ladekarl · 1 shared paper, 2025 · strength 0.21
- Susy Shim · 1 shared paper, 2025 · strength 0.21
- Per Pfeiffer · 1 shared paper, 2025 · strength 0.21
- Eike Gallmeier · 1 shared paper, 2023 · strength 0.12
- Jasmin Schuhbaur · 1 shared paper, 2023 · strength 0.12
- Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.12
- Andrea Tannapfel · 1 shared paper, 2023 · strength 0.12
- Volker Kunzmann · 1 shared paper, 2023 · strength 0.12
- Waldemar H. Uhl · 1 shared paper, 2023 · strength 0.12
- Michael Geißler · 1 shared paper, 2023 · strength 0.12
- Ingo Klein · 1 shared paper, 2023 · strength 0.12
- Detlef Klaus Bartsch · 1 shared paper, 2023 · strength 0.12
- S Daum · 1 shared paper, 2023 · strength 0.12
- Manfred Paul Lutz · 1 shared paper, 2023 · strength 0.12
- Alexander Kleger · 1 shared paper, 2023 · strength 0.12
- Alexander Otto König · 1 shared paper, 2023 · strength 0.12
- Helmut Friess · 1 shared paper, 2023 · strength 0.12
- Uwe A. Wittel · 1 shared paper, 2023 · strength 0.12
- Margaret A. Tempero · 1 shared paper, 2023 · strength 0.12
- Hana Algül · 1 shared paper, 2023 · strength 0.12
- Marko Kornmann · 1 shared paper, 2023 · strength 0.12
- Christiane J. Bruns · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.